20th December 2011, Sydney: Elastagen, a clinical stage medical device company that is pioneering Elastatherapy™ using the human protein Elastin to naturally repair and augment the skin, is pleased to announce the appointment of Xavier Yon to its Board, as a Non-Executive Director.
Xavier Yon is a seasoned healthcare executive with an extensive background in dermatology. Previous roles include executive positions with Pfizer, Solvay, Alcon and most notably as CEO of Galderma for 17 years. During his time at Galderma he built the company from its initial spin out from Alcon to be a world leader in ethical dermatology with over 3,000 employees and $ 2 Billion in revenue today. More recently he has served as a Director of Graceway Pharmaceuticals (USA), which was acquired by Medicis, he is a board member of Photocure (Norway), a pioneer of Photo Dynamic Therapy and, Virbac (France), a global leader in animal health.
Andrew Sneddon, Chairman of Elastagen, said “Xavier’s appointment is another significant milestone for Elastagen as we continue the clinical development of our Elastatherapy™ products for the cosmetic and medical dermatology markets. Xavier brings incredible experience and a wide network in the dermatology industry. We are privileged to have him join the Elastagen team.”
Following his appointment Xavier Yon stated “It is a great pleasure to join Elastagen and I look forward to working with the Board and management to drive this important project forward. Elastagen has a very strong team, a solid scientific base, and is developing what promises to be the next generation of skin treatments for the aesthetic dermatology market. Elastin is a key component of healthy skin and it is exciting to see these new treatments emerging.”
For further information please contact:
Robert Daniels, CEO
+61 (0)2 9209 4054
r.daniels@elastagen.com
College Hill (media enquiries)
Daniel Gooch
+44 (0)20 7866 7866
Daniel.gooch@collegehill.com
About Elastagen Pty Ltd:
Elastagen is a clinical stage medical device company that is pioneering Elastatherapy™ using the human protein Elastin to naturally repair and augment the skin. Skin elasticity deteriorates with age due to the progressive loss of the Elastin protein, one of the three key molecules associated with youthful skin. Two of these molecules, Hyaluronic Acid (HA) and Collagen, are already used in aesthetic dermatology, but the potential for Elastin has remained untapped and offers a novel direction in anti-ageing therapy. Elastagen has pioneered the scientific understanding of Elastin and the Elastagenesis process. Elastagen is also the first company to have succeeded in the scalable commercial GMP compliant manufacture of full length recombinant human Elastin for use in dermatology applications. The Company is currently conducting multiple clinical studies to evaluate the potential of its Elastin formulations to augment the skin and restore elasticity in both cosmetic and medical dermatology applications. Elastagen is located in Sydney, Australia, and is a venture backed private company. Investors include ATP Innovations, Brandon Capital and GBS Ventures. Further information on Elastagen can be found at www.elastagen.com.
